Matthias Kettwig

Title: Matthias Kettwig: Innovator in Sulfatase Deficiency Treatments

Introduction

Matthias Kettwig is a notable inventor based in Göttingen, Germany. He has made significant contributions to the field of medical treatments, particularly focusing on diseases associated with sulfatase deficiencies. His innovative approach has the potential to improve the lives of many individuals suffering from these conditions.

Latest Patents

Kettwig holds a patent for a method aimed at treating diseases related to sulfatase deficiencies. This method involves administering a therapeutically effective amount of at least one retinoid to individuals suffering from lysosomal storage diseases. Specifically, the compounds tazaroten and bexaroten have shown beneficial effects for these patients. The pharmaceutical compositions that include both active agents, tazaroten and bexaroten, provide a ready treatment option, and enhanced results are achieved when at least two active agents are utilized.

Career Highlights

Matthias Kettwig is affiliated with the Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin. His work at this esteemed institution has allowed him to focus on groundbreaking research and development in the medical field. His dedication to improving treatment options for patients with sulfatase deficiencies is commendable.

Collaborations

Kettwig collaborates with several talented individuals in his field, including Lars Schlotawa and Karthikeyan Radhakrishnan. These collaborations enhance the research and development process, leading to more effective treatment solutions.

Conclusion

Matthias Kettwig's innovative work in the treatment of sulfatase deficiencies showcases his commitment to advancing medical science. His patent and ongoing research have the potential to significantly impact the lives of those affected by these diseases.